Canada Markets closed

BriaCell Therapeutics Corp. (BCTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.08+0.31 (+5.37%)
At close: 04:00PM EDT
6.01 -0.06 (-0.99%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close5.77
Open5.75
Bid6.00 x 800
Ask6.10 x 1200
Day's Range5.73 - 6.14
52 Week Range4.06 - 12.47
Volume208,755
Avg. Volume874,963
Market Cap96.75M
Beta (5Y Monthly)1.51
PE Ratio (TTM)N/A
EPS (TTM)-0.29
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
  • Baystreet

    Stocks in play: BriaCell Therapeutics Corp

    Announced a research collaboration agreement with Harvard Medical School in support of a project led ...

  • GlobeNewswire

    BriaCell Enters Research Agreement to Identify Novel Targets for Cancer Treatment

    PHILADELPHIA and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, today announced a research collaboration agreement with Harvard Medical School in support of a project led by Joan S. Brugge, PhD, a faculty member. The project aims to discover new targets that may lead to the development of novel anti

  • GlobeNewswire

    BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal

    Anti-Cancer activity of BriaCell’s lead candidate, Bria-IMT™, in advanced breast cancer patients was published in a leading peer-reviewed publication. Bria-IMT™, through a novel mechanism of action, rapidly destroyed tumors in patients who matched Bria-IMT™ HLA types, supporting BriaCell’s platform strategy of developing off-the-shelf personalized immunotherapy for multiple cancer indications.The clinical data, previously reported, included rapid tumor reduction and extended survival. PHILADELPH